A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. The compound APR‐246 (PRIMA‐1Met/Eprenetapopt) is converted to methylene quinuclidinone (MQ) that targets mutant p53 protein and perturbs cellular antioxidant balance. APR‐246 is currently tested in a phase III clinical trial in myelodysplastic syndrome (MDS). By in vitro , ex vivo, and in vivo models, we show that combined treatment with APR‐246 and inhibitors of efflux pump MRP1/ABCC1 results in synergistic tumor cell death, which is more pronounced in TP53 mutant cells. This is associated with altered cellular thiol status and increased intracellular glutathione‐conjugated MQ (GS‐MQ). Due to the reversibility of MQ conjugation, GS‐MQ forms an intracellular drug reservoir that increases availability of MQ for targeting mutant p53. Our study shows that redox homeostasis is a critical determinant of the response to mutant p53‐targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2 MK‐571 enhances the anti‐tumor activity of APR‐246 in vivo and ex vivo Growth of Eso26 xenografts (R248W mutant TP53) in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. P values determined by one‐way ANOVA with Tukey’s correction at day 18, n is indicated in the figure.Kaplan–Meier plot of time to reach 1,400 mm3 tumor volume in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. Mice that were culled at ethical endpoints prior to reaching a tumor volume of > 1,400 mm3 are marked as censored observations. P values were determined by Log‐rank (Mantel–Cox) test between different treatment groups. n is indicated in the figure.Quantification of Ki67 immunohistochemistry staining of Eso26 xenograft tumors at an early timepoint (5 days) or post‐treatment/late timepoint (> 22 days) after treatment initiation with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg). Dots indicate individual tumors.Quantification of cleaved caspase 3 immunohistochemistry staining of Eso26 xenograft tumors in same tumors as shown in Fig 2C. Dots indicate individual tumors.Representative images of hematoxylin/eosin (H&E) staining and immunostaining of Ki67, cleaved caspase 3 and p53, post‐treatment/late timepoint (> 22 days after treatment initiation) with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg).Growth suppression determined by the ATP‐based CTG assay in colorectal cancer patient‐derived organoids (colo‐PDO) after treatment with APR‐246 +/− MK‐571 (n = 3).IC50 values (µM) APR‐246 +/− 20 μM MK‐571 in indicated PDOs (colo‐PDO or esophageal adenocarcinoma patient‐derived PDO [eso‐PDO]). *P = 0.04, paired t‐test (n = 3 except colo‐PDO2 and eso‐PDO3 where n = 2).Organoid area (in black, left y‐axis) and PI intensity (in red, right y‐axis) of colo‐PDO1 and colo‐PDO2 as determined by image analysis 72 h after treatment with APR‐246 +/− MK‐571 (n = 3).Highest synergy score according to the ZIP model based on growth suppression as shown by CTG assay (ATP‐based) or image analysis (Area and PI) in eso‐PDOs and colo‐PDOs. Scores are shown on a log scale. Score above 0 indicates synergy. Each dot indicates one individual experiment. Data information: TP53 status is indicated. Data are represented as mean ± SEM. See also Fig EV2, Appendix Fig S2 and Appendix Table S2.](https://figures.cochat.ai/paper-figures/7df3289509e14332b66bade13413c882/a-thiol-bound-drug-reservoir-enhances-apr-246-induced-mutant-p53-tumor-cell-figure-2.jpg)











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our data on the ROS-dependent, but most likely TP53-independent mechanism of OvCa cell killing by APR-246 is directly supported by recently published work (21,25).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of a note, the high micromolar concentrations of APR-246 required for OvCa cell killing is consistent with published studies (21,25), and due to intracellular metabolism of the drug to the active product methylene quinuclidinone (MQ)(21).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This model is in keeping with our prior work, and confirmed by others (7, 8, 20), demonstrating that inhibiting cystine uptake with erastin or sulfasalazine synergizes with eprenetapopt both in vitro and in vivo.”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our work supports previous findings reporting that GSH depletion and/or factors that regulate GSH availability are central determinants of eprenetapopt activity in cancer cells (6–8), as opposed to p53 and associated apoptotic machinery.”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our data about ROS-dependent, but most likely TP53-independent mechanism of OvCa cell killing by APR-246 is directly supported by recently published work (17, 21).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Tietze, F. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90064-5 · Cited by 6,047
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“HCT116 TP53 null and R248W cells were generated by targeted disruption of endogenous WT TP53 or knockin of R248W-mutant TP53 (Bunz et al, 1998).”
BackgroundHoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546 · cited 3×
“Data from the luad, lusc, coad, and esca studies of The Cancer Genom Atlas (TCGA) PanCancer Atlas Studies (Hoadley et al, 2018) were downloaded from cBioportal (Cerami et al, 2012; Gao et al, 2013) (https://www.cbioportal.org/).”
BackgroundMethodTHE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“Mutant p53 may also in some settings have gain-of-function (GOF) activities that promote tumor growth (Muller & Vousden, 2014).”
BackgroundBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cited by
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9427 · Cited by 102
“This model is in keeping with our prior work, and confirmed by others ( 7 , 8 , 20 ), demonstrating that inhibiting cystine uptake with erastin or sulfasalazine synergizes with eprenetapopt both in vitro and in vivo.”
InfluentialSelf-citationPharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93
Self-citationDegtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., Frydenberg, M., Grummet, J., Sandhu, S. K., Hickey, T. E., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211020668 · Cited by 77
Self-citation
Metadata
- Authors
- Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., Behrenbruch, C., Simpson, K. J., Hollande, F., Abrahmsen, L., Clemons, N. J., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- University of Cambridge (GB)
- Corresponding author
- Wiman, Klas G
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-14
- Volume
- 13
- Issue
- 2
- Pages
- e10852-e10852
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7863383
- OpenAlex
- W3110888894
- Semantic Scholar
- 90cf97d8adfcfee270b01369013080af9890095b
- Cited by
- 41
- References
- 80
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 7 · 2022: 11 · 2021: 6 · 2020: 2
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Vetenskapsrådet (2017‐01509)
- Cancerfonden (18 0774)
- Barncancerfonden (PR2017‐0106)
- Radiumhemmets Forskningsfonder (171213)
- Knut och Alice Wallenbergs Stiftelse
- Aprea Therapeutics
- Karolinska Institutet
- Department of Health, Australian Government | National Health and Medical Research Council (APP1120293, GNT1164081)
- Department of Health and Human Services, State Government of Victoria (MCRF16002)
- Tour de Cure Foundation (RSP ‐ 0004 ‐ 17/18)
- UKRI | Medical Research Council (RG84369)
- Australian Cancer Research Foundation
- Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program
- Peter MacCallum Cancer Centre Foundation
- University of Melbourne Research Collaborative Infrastructure Program
- Cancer Research UK (RG81771/84119)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- APR-246, PRIMA-1MET, mutant p53, TP53 mutation, glutathione conjugation, redox homeostasis, cancer cell death, myelodysplastic syndrome
- MeSH terms
- Pharmaceutical Preparations, Humans, Mutation, Neoplasms, Quinuclidines, Sulfhydryl Compounds, Tumor Suppressor Protein p53, Cell Death, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. https://app.cochat.ai/papers/10.15252/emmm.201910852
- The paper
- Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., Behrenbruch, C., Simpson, K. J., Hollande, F., Abrahmsen, L., Clemons, N. J., & Wiman, K. G. (2021). A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201910852
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.